BASF Appoints Thomas Biegi for Communications and Government Relations

Key highlights
  • Thomas Biegi will lead BASF's Corporate Communications and Government Relations from April 1, 2026.
  • He succeeds Nina Schwab-Hautzinger and will report to Markus Kamieth.
  • Biegi is currently Head of Communications and Government Affairs at GSK in Germany.
  • He has held senior roles at MorphoSys and Pfizer, focusing on communications.

Leadership Change

Thomas Biegi will take over as head of BASF's Corporate Communications and Government Relations on April 1, 2026. He will succeed Nina Schwab-Hautzinger and report directly to Markus Kamieth, Chairman of the Board of Executive Directors at BASF.

Professional Background

Biegi is an experienced leader in Corporate Affairs, with a strong background in the pharmaceutical and biotech industries. He is currently the Head of Communications and Government Affairs for GSK in Germany.

Previous Roles

Before joining GSK, Biegi served as Senior Vice President and Head of Corporate Affairs at MorphoSys, where he was part of the Executive Committee. He played a key role in communications during MorphoSys's transformation and acquisition by Novartis. Additionally, he held senior positions at Pfizer, managing communications for the global Oncology group and leading the communications team in Germany.

Educational Background

Thomas Biegi holds a Bachelor of Arts in Business Administration and a Master of Arts in Media and Communication Studies from the Freie Universität in Berlin.

Source: BASF

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

2 December 2025
Genmab Names Séverine Lemoine as France GM

Séverine Lemoine will lead operations in France, focusing on product launches and expanding the local presence in oncology.

20 April 2026
GSK's Blenrep approved in China for 2L+ relapsed/refractory multiple myeloma

Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.

25 February 2026
ViiV Healthcare Unveils Data on Twice-Yearly HIV Treatments

VH184 and VH499 show promise for twice-yearly HIV treatment, with improved resistance and tolerability, reducing the need for daily medication.

25 February 2026
ViiV Healthcare: Lotivibart Shows 94% Viral Suppression in Long-Acting HIV Treatment

Lotivibart, combined with CAB LA, maintained viral suppression in 94% of participants. Study progresses to test twice-yearly dosing. Well-tolerated with fewer adverse events in IV group.